The bill proposes the enactment of several new sections within the Revised Code, specifically addressing individualized investigational treatments for patients suffering from life-threatening or severely debilitating illnesses. Key definitions are established, including "eligible facility," "eligible patient," and "individualized investigational treatment," which refers to treatments tailored to an individual's unique genetic profile. The bill outlines the conditions under which eligible patients may request such treatments, the responsibilities of manufacturers and facilities, and the informed consent process required before treatment can commence.

Additionally, the bill clarifies that while health benefit plans may choose to cover the costs associated with individualized investigational treatments, they are not mandated to do so. It also protects physicians from disciplinary actions based solely on their recommendations for these treatments and ensures that patients' heirs are not liable for any debts incurred due to the treatment if the patient passes away. The legislation aims to facilitate access to potentially life-saving treatments while establishing clear guidelines and protections for patients, healthcare providers, and manufacturers involved in the process.